Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Chapple

Showing results (101-110 of 166) with videos related to

Pageof 17
Sort By:
Neurourology and Urodynamics|March 16, 2012
Overactive bladder symptoms and voiding dysfunction in neurologically normal womenMontserrat Espuña-Pons, Linda Cardozo, Christopher Chapple, et al.
BJU International|August 14, 2013
OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urotheliumValerie M Collins, Donna M Daly, Marina Liaskos, et al.
European Urology|November 19, 2013
An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disordersAltaf Mangera, Apostolos Apostolidis, Karl Eric Andersson, et al.
European Urology|August 13, 2013
Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trialPhilip van Kerrebroeck, Christopher Chapple, Ted Drogendijk, et al.
European Urology|August 6, 2014
Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trialsChristopher Chapple, Vik Khullar, Victor W Nitti, et al.
Neurourology and Urodynamics|January 15, 2022
Management strategies and outcome of ureterovaginal fistulae: A systematic review and meta-analysisGunjan Bahuguna, Vikas K Panwar, Ankur Mittal, et al.
BJU International|April 5, 2007
Overactive bladder syndrome in older peopleAdrian S Wagg, Linda Cardozo, Christopher Chapple, et al.
European Urology|July 30, 2014
Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extensionMarcus J Drake, Christopher Chapple, Roman Sokol, et al.
European Urology|August 13, 2017
Reply to Bora Lee and Jae Heon Kim's Letter to the Editor re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402-7Alan D Uren, Nikki Cotterill, Christopher Harding, et al.
European Urology|April 13, 2017
Qualitative Exploration of the Patient Experience of Underactive BladderAlan D Uren, Nikki Cotterill, Christopher Harding, et al.
Pageof 17

Showing results (101-110 of 166) with videos related to

Sort By:
Pageof 17
Neurourology and Urodynamics|March 16, 2012
Overactive bladder symptoms and voiding dysfunction in neurologically normal womenMontserrat Espuña-Pons, Linda Cardozo, Christopher Chapple, et al.
BJU International|August 14, 2013
OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urotheliumValerie M Collins, Donna M Daly, Marina Liaskos, et al.
European Urology|November 19, 2013
An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disordersAltaf Mangera, Apostolos Apostolidis, Karl Eric Andersson, et al.
European Urology|August 13, 2013
Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trialPhilip van Kerrebroeck, Christopher Chapple, Ted Drogendijk, et al.
European Urology|August 6, 2014
Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trialsChristopher Chapple, Vik Khullar, Victor W Nitti, et al.
Neurourology and Urodynamics|January 15, 2022
Management strategies and outcome of ureterovaginal fistulae: A systematic review and meta-analysisGunjan Bahuguna, Vikas K Panwar, Ankur Mittal, et al.
BJU International|April 5, 2007
Overactive bladder syndrome in older peopleAdrian S Wagg, Linda Cardozo, Christopher Chapple, et al.
European Urology|July 30, 2014
Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extensionMarcus J Drake, Christopher Chapple, Roman Sokol, et al.
European Urology|August 13, 2017
Reply to Bora Lee and Jae Heon Kim's Letter to the Editor re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402-7Alan D Uren, Nikki Cotterill, Christopher Harding, et al.
European Urology|April 13, 2017
Qualitative Exploration of the Patient Experience of Underactive BladderAlan D Uren, Nikki Cotterill, Christopher Harding, et al.
Pageof 17